Report cover image

Optic Nerve Diseases Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146992

Description

Optic nerve diseases refer to a group of disorders that affect the optic nerve, leading to vision impairment or loss. Optic neuritis, a common manifestation, is a significant concern in multiple sclerosis (MS), affecting 15 % to 20 % of multiple sclerosis patients as the presenting feature and occurring in 50 percent of patients during their illness. There is a high unmet clinical need for better therapies to treat optic nerve diseases, as current treatment options, such as corticosteroids, offer limited efficacy and do not address long-term outcomes. Furthermore, the growing focus on targeted drug candidates for optic nerve protection and repair is likely to support the growth of the optic nerve diseases pipeline in the coming years.

Report Coverage

The Optic Nerve Diseases Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into optic nerve diseases therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for optic nerve diseases. The optic nerve diseases report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The optic nerve diseases pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with optic nerve diseases treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to optic nerve diseases.

Optic Nerve Diseases Drug Pipeline Outlook

Optic nerve diseases refer to conditions affecting the optic nerve, such as optic neuropathy, which can lead to vision impairment. These disorders occur due to various causes, including ischemia, inflammation, and trauma. Damage to the optic nerve disrupts visual transmission, resulting in visual deficits and potential blindness, posing a significant clinical challenge.

Treatment for optic nerve diseases typically involves corticosteroids to reduce inflammation and manage symptoms. However, these therapies primarily address acute stages and do not prevent long-term damage. Ongoing development of drug candidates aims to protect and regenerate optic nerve tissues, offering hope for better outcomes in the future.

Optic Nerve Diseases Epidemiology

The global optic nerve diseases drug pipeline reflects the growing need for targeted treatments. Optic neuritis, an inflammatory condition linked to multiple sclerosis (MS), presents in 15% to 20% of multiple sclerosis cases and affects 50% of patients during their illness. The incidence is highest in northern latitudes, with 6.4 cases per 100,000 annually in the United States, particularly among White Americans.

Optic Nerve Diseases – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of optic nerve diseases drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Optic Nerve Diseases – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total optic nerve diseases clinical trials.

Optic Nerve Diseases – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the optic nerve diseases pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The optic nerve diseases report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for optic nerve diseases.

Optic Nerve Diseases Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the optic nerve diseases drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed optic nerve diseases therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in optic nerve diseases clinical trials:
  • Neurophth Biological Technology Ltd Co.
  • Argenx
  • 4B Technologies Limited
  • PYC Therapeutics
  • Qlaris Bio, Inc.
  • Pfizer Inc.
  • AbbVie Inc.
Optic Nerve Diseases – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for optic nerve diseases. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of optic nerve diseases drug candidates.

Drug: NR082

Wuhan Neurophth Biotechnology Limited Company is sponsoring a Phase 1/2/3 clinical trial to evaluate NR082's safety and efficacy in treating Leber's Hereditary Optic Neuropathy (LHON), caused by the mitochondrial ND4 gene mutation. The study aims to determine the optimal dose and is expected to enroll approximately 102 participants, with completion anticipated by February 29, 2028.

Drug: QLS-111 Ophthalmic Solution

Qlaris Bio, Inc. is sponsoring a Phase 2 clinical trial to investigate the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in patients with normal tension glaucoma (NTG). The study aims to evaluate QLS-111's effectiveness at two concentrations compared to a vehicle. The trial, set to enroll around 60 participants, is expected to be completed by October 2025.

Drug: PYC-001

The drug PYC-001, sponsored by PYC Therapeutics, is being evaluated in a Phase 1a clinical trial for participants with OPA1 mutation-associated autosomal dominant optic atrophy (ADOA). The objective is to assess the safety and tolerability of a single ascending dose (SAD) of intravitreal PYC-001. The study, with an estimated 18 participants, is expected to be completed by August 2025.

Reasons To Buy This Report

The Optic Nerve Diseases Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for optic nerve diseases. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into optic nerve diseases collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Optic Nerve Diseases – Pipeline Insight Report
  • Which companies/institutions are leading the optic nerve diseases drug development?
  • What is the efficacy and safety profile of optic nerve diseases pipeline drugs?
  • Which company is leading the optic nerve diseases pipeline development activities?
  • What are the current optic nerve diseases commercial assessment?
  • What are the opportunities and challenges present in the optic nerve diseases drug pipeline landscape?
  • What is the efficacy and safety profile of optic nerve diseases pipeline drugs?
  • Which company is conducting major trials for optic nerve diseases drugs?
  • Which companies/institutions are involved in optic nerve diseases collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in optic nerve diseases?
Related Reports

Optic Nerve Diseases Epidemiology

Global Glaucoma Therapeutics Market

Global Glaucoma Surgery Devices Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Optic Nerve Diseases
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Optic Nerve Diseases
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Optic Nerve Diseases: Epidemiology Snapshot
5.1 Optic Nerve Diseases Incidence by Key Markets
5.2 Optic Nerve Diseases – Patients Seeking Treatment in Key Markets
6 Optic Nerve Diseases: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Optic Nerve Diseases: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Optic Nerve Diseases, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Optic Nerve Diseases Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Optic Nerve Diseases Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: NR082
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
11 Drug: Bosentan
12 Other Drugs
13 Optic Nerve Diseases Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
13.1 Comparative Analysis for Mid-Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug: QLS-111 Ophthalmic Solution
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.1.13 Recent Results
13.2.2 Other Drugs
14 Optic Nerve Diseases Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
14.1 Comparative Analysis for Early-Stage Drugs
14.1.1 Study Type
14.1.2 Recruitment Status
14.1.3 Company
14.1.4 Funder Type
14.2 Product Level Analysis*
14.2.1 Drug: PYC-001
14.2.1.1 Product Description
14.2.1.2 Trial ID
14.2.1.3 Sponsor Name
14.2.1.4 Study Type
14.2.1.5 Drug Class
14.2.1.6 Eligibility Criteria
14.2.1.7 Study Record Dates
14.2.1.7.1 First Submitted
14.2.1.7.2 First Posted
14.2.1.7.3 Last Update Posted
14.2.1.7.4 Last Verified
14.2.1.8 Indication
14.2.1.9 Study Design
14.2.1.10 Recruitment Status
14.2.1.11 Enrollment (Estimated)
14.2.1.12 Location Countries
14.2.2 Drug: FB1001
14.2.3 Other Drugs
15 Optic Nerve Diseases Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
15.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
15.1.1 Study Type
15.1.2 Recruitment Status
15.1.3 Company
15.1.4 Funder Type
15.2 Product Level Analysis*
15.2.1 Drug 1
15.2.1.1 Product Description
15.2.1.2 Trial ID
15.2.1.3 Sponsor Name
15.2.1.4 Study Type
15.2.1.5 Drug Class
15.2.1.6 Eligibility Criteria
15.2.1.7 Study Record Dates
15.2.1.7.1 First Submitted
15.2.1.7.2 First Posted
15.2.1.7.3 Last Update Posted
15.2.1.7.4 Last Verified
15.2.1.8 Indication
15.2.1.9 Study Design
15.2.1.10 Recruitment Status
15.2.1.11 Enrollment (Estimated)
15.2.1.12 Location Countries
15.2.2 Other Drugs
16 Optic Nerve Diseases, Key Drug Pipeline Companies
16.1 Neurophth Biological Technology Ltd Co.
16.1.1 Company Snapshot
16.1.2 Pipeline Product Portfolio
16.1.3 Financial Analysis
16.1.4 Recent News and Developments
16.2 Argenx
16.2.1 Company Snapshot
16.2.2 Pipeline Product Portfolio
16.2.3 Financial Analysis
16.2.4 Recent News and Developments
16.3 4B Technologies Limited
16.3.1 Company Snapshot
16.3.2 Pipeline Product Portfolio
16.3.3 Financial Analysis
16.3.4 Recent News and Developments
16.4 PYC Therapeutics
16.4.1 Company Snapshot
16.4.2 Pipeline Product Portfolio
16.4.3 Financial Analysis
16.4.4 Recent News and Developments
16.5 Qlaris Bio, Inc.
16.5.1 Company Snapshot
16.5.2 Pipeline Product Portfolio
16.5.3 Financial Analysis
16.5.4 Recent News and Developments
16.6 Pfizer Inc.
16.6.1 Company Snapshot
16.6.2 Pipeline Product Portfolio
16.6.3 Financial Analysis
16.6.4 Recent News and Developments
16.7 AbbVie Inc.
16.7.1 Company Snapshot
16.7.2 Pipeline Product Portfolio
16.7.3 Financial Analysis
16.7.4 Recent News and Developments
17 Regulatory Framework for Drug Approval, By Region
18 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us